NEW YORK (GenomeWeb News) —Genedata said today that UCB has renewed and expanded an agreement to use two Genedata software platforms in its lead discovery research.
The new agreement will allow UCB to use Genedata's Phylosopher and Expressionist software in its biologics and lead-finding studies for central nervous system disorders and autoimmune and inflammatory disorders that are conducted in the UK and Belgium.
The Expressionist biomarker research software includes public and private data and sample information, and its functions have been expanded to include data from UCB’s molecular profiling technology portfolio. The Phylosopher database integrates links between genome sequences and transcriptomics, proteomic and metabolic data, and other information and annotations, as well as disease-relevant phenotype information.
Financial terms of the agreement were not released.